Q: In this task, you are given a abstract of article and corresponding title of an article. Your task is to generate label "yes" if title is right for article, otherwise generate "no".
Abstract: Background CD19specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed Bcell acute lymphoblastic leukemia (ALL) and longterm remissions in a subgroup of patients. Methods We conducted a phase 1 trial involving adults with relapsed Bcell ALL who received an infusion of autologous T cells expressing the 1928z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and longterm outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. Results A total of 53 adults received 1928z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median followup of 29 months (range, 1 to 65), the median eventfree survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median eventfree survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter longterm survival than did patients with a low disease burden. Conclusions In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 1928z CAR Tcell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069.). Title: LongTerm Followup of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
A:
yes